Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03782168 · ClinicalTrials.gov registry record
Plasma Concentration of Biological Markers in Placental Abruption
A clinical trial, sponsored by University of Arkansas.
- Terminated
- Registry status
- 1
- Enrollment target
NCT03782168 is a clinical trial that was terminated before completion, run by University of Arkansas. The registered enrollment target is 1 participants.
The verdict
NCT03782168 was terminated before completion, sponsored by University of Arkansas.
- TERMINATED
- Registry status
- 1 participants
- Enrollment target
Study Summary
This will be a prospective study conducted on women with a suspected/confirmed diagnosis of placental abruption. Maternal blood samples will be taken at various points during the peripartum period. A healthy group of women admitted for delivery will act as a matched control and will have their blood sampled at similar time points. The primary outcome variables will include the total number of micro-particles, the number of micro-particles from each cell line (platelet, placental, endothelial etc.), and protein markers (specifically; placental growth factor (PlGF), soluble fms-like tyrosine kinase-1 (sFLT-1), vascular endothelial growth factor (VEGF), soluble endoglin (sEng)). Secondary outcomes if will examine the correlation between placental micro-particles, biomarkers, and extent of placental abruption.
Interventions
- OTHER There is no other intervention, only clinical treatment.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2019-01-31 |
| Est. Completion | 2021-08-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03782168
The ClinicalTrials.gov registry entry for NCT03782168 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which There is no other intervention, only clinical treatment. is the first listed.
NCT03782168 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03782168 about?
NCT03782168 is a clinical study titled "Plasma Concentration of Biological Markers in Placental Abruption". This will be a prospective study conducted on women with a suspected/confirmed diagnosis of placental abruption. Maternal blood samples will be taken at various points during the peripartum period. A healthy group of women admitted for delivery will act as a matched control and will have their blood...
What is the current status of trial NCT03782168?
This trial is currently terminated. The enrollment target is 1 participants. The study started on 2019-01-31. Estimated completion is 2021-08-01.
What interventions are being tested in trial NCT03782168?
The interventions under investigation include: There is no other intervention, only clinical treatment. (OTHER).
Who is sponsoring clinical trial NCT03782168?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.